MucopolysaccharidosesNCT07173010
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital
An observational study of Mucopolysaccharidoses and Progressive Pseudorheumatoid Dysplasia, run by Assiut University.
Trial summary
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from… Read more about this study
- Who is it for?
- Ages 1 day to 18 years
- Conditions the study is for
- Mucopolysaccharidoses, Progressive Pseudorheumatoid Dysplasia, Farber Disease
- How many people
- 35 participants
- Where
- No sites listed yet
- Study dates
- Sep 2025to Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 18 years
- All sexes
- Child, Adult
Study population: The study will include all pediatric patients presented with non inflammatory arthropathy based on clinical manifestations, laboratory investigations and imaging up to age of 18 years in the last 3 years (retrospective) and those who will present newly through a duration of one year (preospective). They will be recruited from the inpatient and outpatient clinic of Allergy, Immunology and Rheumatology department at Assuit University Children's hospital.
Who may be able to join
- Infants and children up to 18 years at diagnosis.
- Patients presents with picture of non inflammatory arthropathy as joint deformity, stiffness and skeletal abnormality (arthropathy) with normal inflammatory markers
Who cannot join
- Patients more than 18years.
- Patients presents with painful,hot, tender or red joints (Arthritis) associated with elevated inflammatory markers .
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from inflammatory joint diseases.
Read the detailed description
Arthropathy refers to any disease or abnormal condition of a joint. It includes both inflammatory ( arthritis) and non-inflammatory types. Arthritis involves joint inflammation with symptoms such as pain, swelling, and stiffness, along with elevated inflammatory markers. In contrast, non-inflammatory arthropathy may mimic arthritis but lacks signs of inflammation and typically shows normal inflammatory markers.
Non inflammatory arthropathy can closely mimic juvenile idiopathic arthritis (JIA), leading to frequent misdiagnosis and inappropriate treatment.
These disorders are sometimes incorrectly diagnosed and treated as JIA, patients often do not respond to immunosuppressive treatment, leading to poor compliance, disease progression, and unnecessary exposure to potentially harmful medications.
A high index of suspicion, detailed clinical evaluation, and appropriate imaging are essential to distinguish these mimics from true inflammatory arthritis.
Here's a breakdown of some conditions categorized as non-inflammatory arthropathies:
Mucopolysaccharidoses (MPS) are rare inherited metabolic disorders caused by enzyme deficiencies that impair the breakdown of glycosaminoglycans (GAGs), leading to their accumulation and progressive tissue and organ damage. Patients often present with arthropathy ,joint stiffness alongside hallmark features such as skeletal abnormalities, developmental delays, intellectual disability, cardiac issues, corneal clouding, hearing loss, short stature, dysostosis multiplex, and coarse facial features.However Some attenuated forms of mucopolysaccharidoses (MPS), particularly MPS I (Scheie syndrome), MPS II (attenuated Hunter syndrome), and MPS VI (Maroteaux-Lamy syndrome), may present predominantly with joint stiffness and contractures without significant systemic or cognitive involvement.
Progressive Pseudorheumatoid Dysplasia (PPRD) is a rare autosomal recessive skeletal disorder caused by mutations in the WISP3 gene, crucial for joint cartilage development and function. It leads to progressive degeneration of articular cartilage, primarily affecting the interphalangeal joints. Patients typically present with painless, progressive joint stiffness and enlargement without inflammation, joint contractures, gait abnormalities, and spinal deformities such as scoliosis or kyphosis, resulting in abnormal posture and muscle weakness-related morbidities.
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis (CACP) syndrome is a rare autosomal recessive disorder characterized by congenital or early-onset camptodactyly, non-inflammatory arthropathy with synovial hyperplasia, progressive coxa vara deformity of the hip, and non-inflammatory pericarditis. Joint effusions are typically cool and unresponsive to anti-inflammatory treatments.
Idiopathic Multicentric Osteolysis is a rare autosomal dominant skeletal disorder characterized by progressive osteolysis primarily affecting the carpal and tarsal bones, leading to joint deformities, pain, and mobility loss. Typically presenting in childhood, patients experience arthritic-like episodes, progressive deformities, osteolytic changes on imaging, and varying degrees of disability. Associated features may include short stature, muscle weakness, cardiovascular abnormalities, chronic renal failure, as well as occasional mental retardation and minor facial anomalies.
Infantile Systemic Hyalinosis (ISH) is a rare autosomal recessive fibromatosis caused by mutations in the ANTXR2 (CMG2) gene, resulting in widespread hyaline material deposition in multiple tissues including skin, joints, and internal organs. Clinically, ISH presents with painful joint contractures which may lead to arthrogryposis-like appearance (multiple joint contractures), Progressive stiffness and fixed flexion deformities develop especially in knees, elbows, hips, and fingers ,Limited range of motion,subcutaneous nodules, gingival hypertrophy, osteopenia, failure to thrive, protein-losing enteropathy with diarrhea, and recurrent infections.
Farber disease is a rare, fatal autosomal recessive metabolic disorder caused by mutations in the ASAH1 gene, leading to deficient acid ceramidase enzyme activity and subsequent ceramide accumulation in tissues. Affected children typically present with progressive painful joint stiffness, limited motion, contractures, subcutaneous nodules, and hoarseness due to laryngeal involvement, which can result in breathing difficulties.
Osteogenesis imperfecta (OI) is a genetic connective tissue disorder caused by mutations in the COL1A1 and COL1A2 genes, leading to defective type I collagen synthesis. Characterized by brittle bones with increased fracture risk and low bone density,Skeletal deformities and recurrent fractures contribute to abnormal joint mechanics, resulting in arthropathy, stiffness, reduced mobility, and functional impairment over time. OI also presents with blue sclerae, dentinogenesis imperfecta, short stature, and adult-onset hearing loss. Cardiovascular manifestations such as valvular insufficiencies and aortic root dilation have been reported. Milder symptoms include joint laxity, easy bruising, hernias, and hyperhidrosis.
- Conditions
- Mucopolysaccharidoses, Progressive Pseudorheumatoid Dysplasia, Farber Disease, Osteogenesis Imperfecta, Infantile Systemic Hyalinosis, Idiopathic Multicentric Osteolysis
- Medical subject headings
- Mucopolysaccharidoses, Arthropathy, progressive pseudorheumatoid, of childhood, Farber Lipogranulomatosis, Osteogenesis Imperfecta, Hyaline Fibromatosis Syndrome, Osteolysis, Essential
What is being measured
The primary outcome is the main question the study is designed to answer.
To diagnose most common causes of non inflammatory arthropathy
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from inflammatory joint diseases
Measured: 1year
Secondary outcomes (1)
To avoid misdiagnosis as inflammatory arthropathy
To Avoid use of unnecessary treatment in patients with non inflammatory arthropathy who wrongly diagnosed as inflammatory arthropathy
Measured: 1year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2025
- Study startSep 2025 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for MucopolysaccharidosesStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nora Ammar Shawket, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07173010
- Sponsor's protocol ID
- Non inflammatory arthropathy
- Status last verified
- Sep 2025
- First submitted
- 6 Sep 2025
- Last updated
- 15 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Alfadhli F, Alrehaili L, Bindekhayel JN, Alzamil L, Alrehaili A, Hussain Z. A Rare Presentation of a 12-Year-Old With Systemic Infantile Hyalinosis: A Case Report and Review of the Literature. Cureus. 2024 Aug 9;16(8):e66495. doi: 10.7759/cureus.66495. eCollection 2024 Aug.
PubMed 39246942Mohammed SE, Mohammed MM, Saeed M, Al Zahrani D, Alasmari BG. Infantile Systemic Hyalinosis: A Case Report and Literature Review. Cureus. 2023 Oct 5;15(10):e46519. doi: 10.7759/cureus.46519. eCollection 2023 Oct.
PubMed 37927741Sands MS. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol Med. 2013 Jun;5(6):799-801. doi: 10.1002/emmm.201302781. Epub 2013 May 13. No abstract available.
PubMed 23666771Maatallah K, Boussaa H, Lassoued Ferjani H, Kaffel D, Hamdi W. Progressive pseudorheumatoid dysplasia: A rare entity mimicking juvenile idiopathic arthritis. Clin Case Rep. 2021 Aug 16;9(8):e04670. doi: 10.1002/ccr3.4670. eCollection 2021 Aug.
PubMed 34430024Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12. doi: 10.1093/rheumatology/ker394.
PubMed 22210669Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017 Jul;121(3):227-240. doi: 10.1016/j.ymgme.2017.05.016. Epub 2017 May 26.
PubMed 28595941Ablin DS. Osteogenesis imperfecta: a review. Can Assoc Radiol J. 1998 Apr;49(2):110-23.
PubMed 9561014Carnevale A, Canun S, Mendoza L, del Castillo V. Idiopathic multicentric osteolysis with facial anomalies and nephropathy. Am J Med Genet. 1987 Apr;26(4):877-86. doi: 10.1002/ajmg.1320260415.
PubMed 3591830Tasar M, Eyileten Z, Kasimzade F, Ucar T, Kendirli T, Uysalel A. Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome. Turk J Pediatr. 2014 Nov-Dec;56(6):684-6.
PubMed 26388606Bhavani GS, Al Rashdi S, Shah H, Shukla A, Dalal A, Girisha KM. Progressive Pseudorheumatoid Dysplasia. 2015 Nov 25 [updated 2026 Apr 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK327267/
PubMed 26610319Al-Mayouf SM. Noninflammatory disorders mimic juvenile idiopathic arthritis. Int J Pediatr Adolesc Med. 2018 Mar;5(1):1-4. doi: 10.1016/j.ijpam.2018.01.004. Epub 2018 Feb 24.
PubMed 30805524
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital
- ClinicalTrials.gov ID
- NCT07173010
- Acronym / sponsor ID
- Non inflammatory arthropathy
- Conditions
- Mucopolysaccharidoses, Progressive Pseudorheumatoid Dysplasia, Farber Disease, Osteogenesis Imperfecta, Infantile Systemic Hyalinosis, Idiopathic Multicentric Osteolysis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 15 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from inflammatory joint diseases.
Detailed description
Arthropathy refers to any disease or abnormal condition of a joint. It includes both inflammatory ( arthritis) and non-inflammatory types. Arthritis involves joint inflammation with symptoms such as pain, swelling, and stiffness, along with elevated inflammatory markers. In contrast, non-inflammatory arthropathy may mimic arthritis but lacks signs of inflammation and typically shows normal inflammatory markers.
Non inflammatory arthropathy can closely mimic juvenile idiopathic arthritis (JIA), leading to frequent misdiagnosis and inappropriate treatment.
These disorders are sometimes incorrectly diagnosed and treated as JIA, patients often do not respond to immunosuppressive treatment, leading to poor compliance, disease progression, and unnecessary exposure to potentially harmful medications.
A high index of suspicion, detailed clinical evaluation, and appropriate imaging are essential to distinguish these mimics from true inflammatory arthritis.
Here's a breakdown of some conditions categorized as non-inflammatory arthropathies:
Mucopolysaccharidoses (MPS) are rare inherited metabolic disorders caused by enzyme deficiencies that impair the breakdown of glycosaminoglycans (GAGs), leading to their accumulation and progressive tissue and organ damage. Patients often present with arthropathy ,joint stiffness alongside hallmark features such as skeletal abnormalities, developmental delays, intellectual disability, cardiac issues, corneal clouding, hearing loss, short stature, dysostosis multiplex, and coarse facial features.However Some attenuated forms of mucopolysaccharidoses (MPS), particularly MPS I (Scheie syndrome), MPS II (attenuated Hunter syndrome), and MPS VI (Maroteaux-Lamy syndrome), may present predominantly with joint stiffness and contractures without significant systemic or cognitive involvement.
Progressive Pseudorheumatoid Dysplasia (PPRD) is a rare autosomal recessive skeletal disorder caused by mutations in the WISP3 gene, crucial for joint cartilage development and function. It leads to progressive degeneration of articular cartilage, primarily affecting the interphalangeal joints. Patients typically present with painless, progressive joint stiffness and enlargement without inflammation, joint contractures, gait abnormalities, and spinal deformities such as scoliosis or kyphosis, resulting in abnormal posture and muscle weakness-related morbidities.
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis (CACP) syndrome is a rare autosomal recessive disorder characterized by congenital or early-onset camptodactyly, non-inflammatory arthropathy with synovial hyperplasia, progressive coxa vara deformity of the hip, and non-inflammatory pericarditis. Joint effusions are typically cool and unresponsive to anti-inflammatory treatments.
Idiopathic Multicentric Osteolysis is a rare autosomal dominant skeletal disorder characterized by progressive osteolysis primarily affecting the carpal and tarsal bones, leading to joint deformities, pain, and mobility loss. Typically presenting in childhood, patients experience arthritic-like episodes, progressive deformities, osteolytic changes on imaging, and varying degrees of disability. Associated features may include short stature, muscle weakness, cardiovascular abnormalities, chronic renal failure, as well as occasional mental retardation and minor facial anomalies.
Infantile Systemic Hyalinosis (ISH) is a rare autosomal recessive fibromatosis caused by mutations in the ANTXR2 (CMG2) gene, resulting in widespread hyaline material deposition in multiple tissues including skin, joints, and internal organs. Clinically, ISH presents with painful joint contractures which may lead to arthrogryposis-like appearance (multiple joint contractures), Progressive stiffness and fixed flexion deformities develop especially in knees, elbows, hips, and fingers ,Limited range of motion,subcutaneous nodules, gingival hypertrophy, osteopenia, failure to thrive, protein-losing enteropathy with diarrhea, and recurrent infections.
Farber disease is a rare, fatal autosomal recessive metabolic disorder caused by mutations in the ASAH1 gene, leading to deficient acid ceramidase enzyme activity and subsequent ceramide accumulation in tissues. Affected children typically present with progressive painful joint stiffness, limited motion, contractures, subcutaneous nodules, and hoarseness due to laryngeal involvement, which can result in breathing difficulties.
Osteogenesis imperfecta (OI) is a genetic connective tissue disorder caused by mutations in the COL1A1 and COL1A2 genes, leading to defective type I collagen synthesis. Characterized by brittle bones with increased fracture risk and low bone density,Skeletal deformities and recurrent fractures contribute to abnormal joint mechanics, resulting in arthropathy, stiffness, reduced mobility, and functional impairment over time. OI also presents with blue sclerae, dentinogenesis imperfecta, short stature, and adult-onset hearing loss. Cardiovascular manifestations such as valvular insufficiencies and aortic root dilation have been reported. Milder symptoms include joint laxity, easy bruising, hernias, and hyperhidrosis.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 1 day to 18 years
- Sex
- All
- Age groups
- Child, Adult
- Study population
- The study will include all pediatric patients presented with non inflammatory arthropathy based on clinical manifestations, laboratory investigations and imaging up to age of 18 years in the last 3 years (retrospective) and those who will present newly through a duration of one year (preospective). They will be recruited from the inpatient and outpatient clinic of Allergy, Immunology and Rheumatology department at Assuit University Children's hospital.
Key inclusion criteria (2 listed)
- Infants and children up to 18 years at diagnosis.
- Patients presents with picture of non inflammatory arthropathy as joint deformity, stiffness and skeletal abnormality (arthropathy) with normal inflammatory markers
Key exclusion criteria (2 listed)
- Patients more than 18years.
- Patients presents with painful,hot, tender or red joints (Arthritis) associated with elevated inflammatory markers .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To diagnose most common causes of non inflammatory arthropathy
Time frame: 1year
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from inflammatory joint diseases
1 secondary outcome
To avoid misdiagnosis as inflammatory arthropathy
Time frame: 1year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Results publication: PubMed 39246942Alfadhli F, Alrehaili L, Bindekhayel JN, Alzamil L, Alrehaili A, Hussain Z. A Rare Presentation of a 12-Year-Old With Systemic Infantile Hyalinosis: A Case Report and Review of the Literature. Cureus. 2024 Aug 9;16(8):e66495. doi: 10.7759/cureus.66495. eCollection 2024 Aug.
- Results publication: PubMed 37927741Mohammed SE, Mohammed MM, Saeed M, Al Zahrani D, Alasmari BG. Infantile Systemic Hyalinosis: A Case Report and Literature Review. Cureus. 2023 Oct 5;15(10):e46519. doi: 10.7759/cureus.46519. eCollection 2023 Oct.
- Results publication: PubMed 23666771Sands MS. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol Med. 2013 Jun;5(6):799-801. doi: 10.1002/emmm.201302781. Epub 2013 May 13. No abstract available.
- Results publication: PubMed 34430024Maatallah K, Boussaa H, Lassoued Ferjani H, Kaffel D, Hamdi W. Progressive pseudorheumatoid dysplasia: A rare entity mimicking juvenile idiopathic arthritis. Clin Case Rep. 2021 Aug 16;9(8):e04670. doi: 10.1002/ccr3.4670. eCollection 2021 Aug.
- Results publication: PubMed 22210669Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12. doi: 10.1093/rheumatology/ker394.
- Results publication: PubMed 28595941Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017 Jul;121(3):227-240. doi: 10.1016/j.ymgme.2017.05.016. Epub 2017 May 26.
- Results publication: PubMed 9561014Ablin DS. Osteogenesis imperfecta: a review. Can Assoc Radiol J. 1998 Apr;49(2):110-23.
- Results publication: PubMed 3591830Carnevale A, Canun S, Mendoza L, del Castillo V. Idiopathic multicentric osteolysis with facial anomalies and nephropathy. Am J Med Genet. 1987 Apr;26(4):877-86. doi: 10.1002/ajmg.1320260415.
- Results publication: PubMed 26388606Tasar M, Eyileten Z, Kasimzade F, Ucar T, Kendirli T, Uysalel A. Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome. Turk J Pediatr. 2014 Nov-Dec;56(6):684-6.
- Results publication: PubMed 26610319Bhavani GS, Al Rashdi S, Shah H, Shukla A, Dalal A, Girisha KM. Progressive Pseudorheumatoid Dysplasia. 2015 Nov 25 [updated 2026 Apr 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK327267/
- Results publication: PubMed 30805524Al-Mayouf SM. Noninflammatory disorders mimic juvenile idiopathic arthritis. Int J Pediatr Adolesc Med. 2018 Mar;5(1):1-4. doi: 10.1016/j.ijpam.2018.01.004. Epub 2018 Feb 24.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Arthritis . Bethesda (MD): National Institutes of Health; 2022 Nov.Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Mucopolysaccharidoses
Active, not recruitingObservational study
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I
Active, not recruitingPhase 2
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Mucopolysaccharidosis Disorders, Hurler Syndrome
RecruitingPhase 1/2
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Mucopolysaccharidosis Type IIIA
Enrolling by invitationPhase 2/3
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Mucopolysaccharidosis II
Enrolling by invitationPhase 2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Achondroplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Mucopolysaccharidoses and Progressive Pseudorheumatoid Dysplasia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nora Ammar Shawket (+201129859299, nrnr87355@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To diagnose most common causes of non inflammatory arthropathy (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07173010, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.